medications in managing difficult behaviors€¦ · the mood stabilizers mood stabilizers do not...
TRANSCRIPT
4/4/2018
1
MEDICATIONS IN MANAGING DIFFICULT
BEHAVIORSA REALITY CHECK
reꞏalꞏiꞏty checkNoun informalan occasion on which one is reminded of the state of things in the real world.
ROBERT LACOSTE, MDMEDICAL DIRECTOR,
BEHAVIORAL CARE SOLUTIONS
4/4/2018
5
THE ACETYLCHOLINESTERASE INHIBITORS
LESSON #2
The average benefit of the ACI is a smal improvement
in cognition, neuropsychiatric symptoms and ADLs.
THE ACI• A 2004 study (Lancet) revealed MMSE scores were 0.8 points
better over the first 2 years (1point better on BADLS), but
found no benefit in regards to behavioral symptoms,
institutionalization or progression of disability.
4/4/2018
6
THE ACIA Cohcrane review (2006) revealed improvements in cognitive
function on average of 2.7 points (3.8%) on the ADAS-cog scale.
No difference between agents.
Main side effects were nausea, vomiting and diarrhea (29% left
the treatment group vs 18% for the placebo group).
THE ACIHowever, other studies have found otherwise. Wallin AK et al
(Dement Geriatr Cogn Disord, 2007) followed outpatients for 3
years on donepezil, with a mean change in MMSE of 3.8 points,
with 30% (of the 38% left) of them unchanged or improved in
global assessment at the endpoint.
THE ACIIn another study, Alzheimer’s patients treated with rivastigmine
had a reduced risk of initiating therapy with an antipsychotic
drug (9.8%) compared to patients not receiving it (25.6%).
This suggests that treatment with an ACI might delay the
emergence of behavioral symptoms (Suh DC, Drugs Aging, 2004)
4/4/2018
7
THE ACILanctot et al (CMAJ, 2003) reported in a meta-analysis that the
proportion of responders in excess of the placebo rate was 9%.
In addition, NNT to achieve stabilization or better was 7, and for
minimal improvement or better 12.
THE ACINo clear guidelines as to when/if to withdraw therapy.
Literature supports continuing treatment unless significant side
effects, cost, or faster decline after initiating therapy.
Some studies, although not all, have reported cognitive decline
and behavioral symptoms after discontinuation.
4/4/2018
8
THE ACIThe mean effect is not clinically significant.
The majority of patients do not benefit practically from the ACI.
A small minority (10-15%) does.
However, it is not possible to identify this subgroup of patients
before nor during therapy.
MEMANTINE
MEMANTINEAlso of small/modest benefit, either by itself or in combination with
an ACI.
A study in the NEJM (2012) reported MMSE scores of 1.2 points
higher and 1.5 points lower on the BADLS. No statistically significant
benefit for neuropsychiatric symptoms as measured using the NPI.
Better tolerated than the ACI, with dizziness as main side effect.
4/4/2018
9
MEMANTINEConflicting data on benefit for neuropsychiatric symptoms, with
some studies showing benefit and others not.
One study (Vidal JS et al, Neuroepidemiology, 2008) found 39-
50% more prescriptions for psychotropics before initiation with
memantine and stabilization (53%) thereafter.
LESSON #3As with the ACI, mixed results suggesting no practical benefit for
most patients, with or w/o combination therapy.
A few studies point to practical significance, possibly delaying
the emergence of behavioral symptoms for a minority of patients.
THE ANTIDEPRESSANTS
4/4/2018
10
THE ANTIDEPRESSANTSStudies with SSRIs have produced mixed results.
Usually well tolerated, with drop out rates similar to placebo.
May be useful in the management of agitation and psychosis.
Citalopram and sertraline in particular.
THE ANTIDEPRESSANTSPollock et al (Amer J of Geriatr Psychiatry, 2007) found citalopram
as effective as risperidone for the treatment of psychosis and agitation.
Porsteinsson et al (JAMA, 2014) found that 40% (vs 26% placebo) of treated patients with citalopram were “much or very much improved” using ADCS-CGIC, meaning a difference of 14%.
They used 30 mg however, and the QT interval was affected (18 msec.). Not enough patients were on 20 mg to generalize the findings.
4/4/2018
11
THE ANTIDEPRESSANTSCitalopram lengthens the QTC in a dose dependent manner, and
dosage is capped at 20 mg for those over 60 or taking a CYP2C19 inhibitor (e.g. omeprazole).
In addition, fluoxetine is a strong CYP2D6 3A4 inhibitor while paroxetine is a potent CYP 2D6 inhibitor. Using these agents could lead to significant drug interactions.
THE ANTIDEPRESSANTS
Trazodone did not differentiate from placebo in 3 studies.
Highly antihistaminic, but no anticholinergic effect.
No serotonergic reuptake inhibition under 300 mg.
LESSON #4The data on citalopram is the best data available.
It shows that 14% of patients treated had a response that can
be attributed to the medication.
This again suggests that a minority of patients will derive
practical significance from the use of antidepressants.
4/4/2018
12
THE MOOD STABILIZERS
THE MOOD STABILIZERSMood stabilizers do not stabilize moods. They are either
antimanic drugs or antidepressant agents, with lithium and
lamotrigine being the only agents with an FDA indication for
prophylaxis.
THE MOOD STABILIZERS“The updated review corroborates the earlier findings that
valproate preparations are ineffective in treating agitation
among demented patients, and that valproate therapy is
associated with an unacceptable rate of adverse effects.”
Cochrane review 2009
4/4/2018
13
THE MOOD STABILIZERSIn 2012, Abbott Laboratories was assessed $1.6 billion in civil
and criminal penalties for illegally marketing Depakote in nursing
homes to control agitation and aggression in patients with
dementia.
THE MOOD STABILIZERSA 1998 Am J Psychiatry study found benefit for agitation with
carbamazepine with good tolerability, with reduction in BPRS scores of -7.7 for carbamazepine vs -0.9 for the placebo group.
A 2005 JAMA review cited 2 studies with conflicting results.
3 main concerns with this agent: it affects blood elements, has significant anticholinergic properties, and is a CYP P450 enzyme inducer, thereby increasing clearance of many drugs.
4/4/2018
14
THE MOOD STABILIZERSGabapentin: mild side effect profile, but unproven efficacy.
Oxcarbazepine: a 2009 (Sommer et al) randomnized, double blind, placebo-controlled study found no benefit.
Lamotrigine: advocated on the basis of case reports, but no RCT published to date.
Lithium: case studies show it to be ineffective. No RCT.
LESSON #5Among mood stabilizers, carbamazepine is the only agent with
evidence of efficacy for neuropsychiatric symptoms.
Because its use is fraught with significant side-effects and drug
interactions, carbamazepine could be a 3rd line agent.
4/4/2018
15
THE BENZODIAZEPINES
THE BENZODIAZEPINESBilliotti de Gage et al (BMJ, 2014) reported that the use of BZP
was associated with a 43-51% greater risk of being diagnosed
with AD.
This was only for use greater than 3 months, and the association
was stronger with longer duration and longer acting agents.
4/4/2018
16
THE BENZODIAZEPINESHowever, another study (Gray S et al BMJ, 2016) did not
support a causal association between BZP exposure and
dementia.
Oddly, low use was associated with a slightly higher risk (1.27),
suggesting possibly reverse causation.
THE BENZODIAZEPINES13% of nursing home residents were prescribed a BZD in 2004
(Stevenson et al, Am J Geriatr Psychiatry, 2010).
Some short term double blind studies have shown benefit for
acute agitation.
THE BENZODIAZEPINESSome studies have also shown greater cognitive decline with BZP,
but such findings were confounded by polypharmacy.
BZP have been linked with significant ADR including falls,
delirium, dependency and paradoxical agitation.
4/4/2018
17
LESSON #6They have a role in the treatment of acute agitation.
They are best used on an as needed basis, or for short periods
on a scheduled basis.
Short acting agents are preferred (alprazolam, lorazepam).
NUEDEXTA
4/4/2018
18
NUEDEXTAFDA approved in 2011 for pseudobulbar affect (PBA), a
condition which affects less than 1% of the population, usually
stemming from ALS or MS.
Since 2012, the number of capsules dispensed to LTC facilities
has gone up 400%.
NUEDEXTAOnly one RCT study (Cummings et al, JAMA 2015).
Showed reduction in NPI agitation/aggression scale scores of 50.7%
(drug) against 26.4% (placebo), and 45.1% (vs 27.1%) were judged
to have a “moderate or marked improvement” on the ADCS CGIC.
Main side effects were falls (9 vs 4%), diarrhea (6 vs 3%) and UTI (5
vs 4%). Because of quinidine, it can prolong the QTC.
4/4/2018
19
NUEDEXTAThe authors felt that the findings had clinical significance (18% responded
to the drug).
More studies are needed to see if there is a role for this agent.
Cost is a significant issue.
Quinidine is a CYP2D6 inhibitor, which can affect many other drugs. It is a CYP3A4 substrate and Nuedexta should not be used with 3A4 inhibitors.
LESSON #7
Despite limited evidence and modest benefit, Nuedexta could be
a third line agent, following trial of an ACI and antidepressant,
and before starting an antipsychotic.
THE ANTIPSYCHOTICS
4/4/2018
20
THE ANTIPSYCHOTICSIn 2005, the FDA issued a black-box warning for second
generation antipsychotics about an increased risk of death in elderly dementia patients. In 2011, it was added to the labels of first-generations agents.
Prevalence of use among NH residents (at least 100 days) was 15.7% in 2017, down from 23.9% in 2011 (CMS data).
THE ANTIPSYCHOTICS
4/4/2018
21
THE ANTIPSYCHOTICSSubsequent studies have confirmed theses findings (JAMA 2005,
Lancet Neurol 2009), with causes of death being cardiac (25%), CVA (8%), and pulmonary disease (8%).
This greater risk is not unique to the elderly or those with dementia, since younger patients with any diagnosis are 4.1 times more likely to die than age matched controls (Murray-Thomas T et al, Cardiovasc Psychiatry Neurol 2013).
THE ANTIPSYCHOTICSThe magnitude of the absolute mortality risk may be greater
than previously estimated.
Maust DT et al (JAMA Psychiatry 2015) found such to be 3.8 %
for haloperidol, 3.7% for risperidone, 2.5% for olanzapine and
2.0 for quetiapine, with NNH respectively of 26, 27, 40 and 50.
THE ANTIPSYCHOTICSIn addition, the evidence suggests that FGA may have a greater
risk of mortality than SGA (Gill SS et al, Ann Intern Med 2007).
Furthermore, higher doses correlate as well, and the effect has
been noted as long as 180 days after initiation of therapy.
4/4/2018
22
THE ANTIPSYCHOTICSCMS guidelines are that antipsychotic medications can be
considered for elderly residents with dementia, but only after
medical, physical, functional, psychological, emotional,
psychiatric, social and environmental causes (of behaviors) have
been identified and addressed.
THE ANTIPSYCHOTICS2 meta-analyses on typical antipsychotics found them to have
modest benefit, with an effect size of .18, with no difference
between agents (J Amer Geriatr Soc, 1990).
4/4/2018
23
THE ANTIPSYCHOTICSMaher, AR et al (JAMA, 2011) reviewed 18 RCTs and found
aripiprazole, olanzapine and risperidone to have modest benefit, but not quetiapine.
The effect size was small (0.12-0.20), meaning that the average person in the treatment group would score better than 58% of those in the control group.
THE ANTIPSYCHOTICSThat same study (JAMA, 2011) reported a 35% improvement in
NPI scores vs baseline.
However, the difference in pooled NPI total scores between the treatment group and the placebo group was only 3.41 points.
No difference between agents, but only risperidone is licensed in the UK (2008) for the short term treatment of persistent aggression in Alzheimer’s dementia.
4/4/2018
24
THE ANTIPSYCHOTICSOverall, the rates of discontinuation of treatment among the four
study groups ranged from 77 to 85%. Although the differences
among the groups may have been significant in a larger trial, our
findings suggest that there is no large clinical benefit of treatment
with atypical antipsychotic medications as compared with
placebo (Schneider L et al, NEJM, 2006).
THE ANTIPSYCHOTICS
THE ANTIPSYCHOTICSLow potency FGA are sedating and have anticholinergic activity.
High potency FGA have a high incidence of EPS and TD.
SGA have side effects of weight gain, diabetes, dyslipidemia, QT prolongation, orthostatic hypotension, EPS, TD, prolactin elevation, sedation and falls.
4/4/2018
25
LESSON # 8When nonpharmacologic interventions and safer pharmacologic
approaches fail to manage neuropsychiatric symptoms, and they
result in severe distress or safety issues, treatment with an
antipsychotic may become necessary.
4/4/2018
26
LESSON #9Since their effect size is small and the risks significant in terms of
mortality and morbidity, their use should be temporary and
subject to frequent reassessment.
4/4/2018
27
RECOMMENDATIONSIf behaviors permit, the use of ACI and/or memantine is an
appropriate first line treatment for neuropsychiatric symptoms.
If already on an ACI, optimize dose and/or add memantine.
There are the only FDA approved agents for Alzheimer’s
patients.
4/4/2018
28
RECOMMENDATIONSAntidepressants should be second line agents, unless dealing with
depression/anxiety.
There is some evidence for the use of citalopram and sertraline.
Other agents could be used as well, but avoid fluoxetine,
fluvoxamine, paroxetine, and bupropion because of drug
interactions.
RECOMMENDATIONSCarbamazepine is the only mood stabilizer with some evidence
of efficacy.
However, it has BBW for serious dermatologic reactions as well as aplastic anemia and agranulocytosis.
Its anticholinergic side effects and drug interactions (3A4 inducer) make its use impractical, but it could be used before an antipsychotic.
RECOMMENDATIONSThe benzodiazepines are best used for acute behaviors for a
short period of time or on an as needed basis.
There is no evidence for their chronic use to prevent or manage
difficult behaviors.
4/4/2018
29
RECOMMENDATIONSNuedexta could be a third or fourth line agent, before using an
antipsychotic, but the risks are significant in terms of QT
prolongation and drug interactions.
RECOMMENDATIONSShould the behaviors be severe and/or distressing enough, and
refractory to other agents, and endanger safety, a trial of an
antipsychotic could be initiated.
SGA are preferred over FGA.
RECOMMENDATIONSHowever, such an agent should be discontinued or changed if no
benefit accrues.
Should the behaviors lessen or abate, a GDR is still indicated in
the near future, because…
4/4/2018
31
CONCLUSIONSManaging difficult behaviors is a COMPLEX problem.
These drugs were not designed for such use, and none of them came from an understanding of the etiologies for such behaviors.
For most patients, there is no benefit from the expectations they might have from taking a pill, as often they have no awareness or expectations of taking such an agent.
As a result, benefit and effect size are small.
4/4/2018
32
CONCLUSIONSConsequently, any improvement, especially if significant, has to
be viewed with skepticism and cannot be attributed solely to
medication.
4/4/2018
33
CONCLUSIONSThirdly, the significant risks associated with most of these agents
urge us to substantiate that any improvement stems (at least in
part) from their use.
That is the rationale behind the GDR of these agents.
4/4/2018
34
CONCLUSIONSFinally, a resumption of behaviors after a GDR does not
necessarily mean that it failed, especially if it does not occur
shortly thereafter, because you’re now…
SMARTER.